
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.
      Patients are stratified according to hydroxyurea use.

      Patients are randomized to treatment poloxamer 188 or placebo. Treatment begins within 12
      hours of presentation with crisis. Patients receive poloxamer 188 or placebo by continuous
      infusion for 48 hours. Pain is assessed before, during, and after treatment.

      Patients are followed on days 7-14 and 28-35.
    
  